
Sharon Mates, Intra-Cellular Therapies CEO
Intra-Cellular Therapies gets a boost on PhIII depression drug data
Biotech Intra-Cellular Therapies touting new data Tuesday for its drug designed to treat major depressive disorder.
The biotech shared results from its Study 403 investigating lumateperone, or Caplyta, as a monotherapy to treat major depressive episodes. The study looked at major depressive disorder (MDD) and bipolar depression with “mixed features.” The trial had three populations: participants with both MDD and bipolar depression, patients with only MDD and patients with only bipolar depression.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters